Shots: Polpharma Biologics has signed a licensing agreement with Brazil-based Libbs Farmacêutica for an autoimmune biosimilar Under this strategic partnership, Polpharma Biologics is fully responsible for the development and manufacturing of the product Libbs will exclusively handle the product’s commercialization, marketing, and distribution in the Brazilian market Ref: Polpharma Biologics | Image: Polpharma Biologics | Press ReleaseRelated News:- Polpharma Biologics Launches…
